Main Menu

Oncology product sales and patent expiration: A policy brief

Richard Manning, Fred Selck
June 2, 2017
Read the brief here

Expressions of concern about prescription drug prices and prescription drug spending are widespread. Among the product classes that have drawn attention is oncology. New oncology therapies exhibit a typical life cycle of changing sales over time, particularly when generics enter the market. As patents expire, expenditures on oncology therapies will be affected. This policy brief examines the life cycle of four specific oncology therapies.

Jump to Page

We use cookies to optimize the performance of this site and give you the best user experience. By clicking "Accept," you agree to our use of cookies.

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.